Hexafluorenium

Summary

Hexafluorenium (CHEMBL1201349) is an approved small molecule (ATC M03AC05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03AC05
• Chemistry: 502.7 Da · C36H42N2+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201349
Name	Hexafluorenium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3601
ATC	M03AC05
Molecular formula	C36H42N2+2
Molecular weight	502.7
InChIKey	HDZAQYPYABGTCL-UHFFFAOYSA-N

SMILES: C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46

IUPAC name: 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium

Also known as: Hexafluorenium cation, Hexafluorenium ion, Hexafluronium, HEXAFLUORENIUM, hexafluronium

Parent form; salt/anhydrous children: CHEMBL1200933

Patent coverage: 170 distinct patent families (664 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 659 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	7.17	AC50	67.1	nM	CHEMBL_ACT_25194237
ACHE	6.77	AC50	171.4	nM	CHEMBL_ACT_25142253
CHRM2	6.29	AC50	513.8	nM	CHEMBL_ACT_25195441
HTR1A	6.06	AC50	867.6	nM	CHEMBL_ACT_25164729
OPRM1	5.99	AC50	1030	nM	CHEMBL_ACT_25157880
SLC6A2	5.84	AC50	1437	nM	CHEMBL_ACT_25145705
ADRA2A	5.66	AC50	2187	nM	CHEMBL_ACT_25156134
HRH3	5.57	AC50	2721	nM	CHEMBL_ACT_25199237
SLC6A4	5.52	AC50	3021	nM	CHEMBL_ACT_25151032
ADRA1A	5.51	AC50	3085	nM	CHEMBL_ACT_25218597
SLC6A3	5.35	AC50	4496	nM	CHEMBL_ACT_25124664
CHRM1	5.13	AC50	7410	nM	CHEMBL_ACT_25209955

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).